Skip to main content
ARWR logo

ARWR · Arrowhead Pharmaceuticals, Inc. · Executive Compensation

Track ARWR — free
Market Cap
$5.85B
Shares
141.37M
Volume · Nov 20 3.91M Avg daily vol (3M) 2.07M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2024
Executive Total
Christopher Anzalone $12,423,473
Patrick O’Brien $3,933,570
Kenneth A. Myszkowski $3,512,376
James Hamilton $3,487,444
Javier San Martin $3,456,564
Tracie Oliver $3,076,780
Fiscal 2023
Executive Total
Christopher Anzalone $9,918,093
Patrick O’Brien $3,310,337
Kenneth A. Myszkowski $3,119,143
Javier San Martin $3,095,982
James Hamilton $3,046,943
Tracie Oliver $873,822
Fiscal 2022
Executive Total
Christopher Anzalone $12,031,969
Kenneth A. Myszkowski $4,739,552
Patrick O’Brien $4,727,863
James Hamilton $4,323,314
Tracie Oliver $2,744,471
Javier San Martin $704,744
Fiscal 2021
Executive Total
Christopher Anzalone $24,703,855
Patrick O’Brien $5,336,926
Kenneth A. Myszkowski $5,333,570
James Hamilton $4,509,947
Javier San Martin $644,746
Tracie Oliver —
Fiscal 2020
Executive Total
Bruce Given $16,343,808
Bruce Given, M.D. $16,343,808
Christopher Anzalone $14,294,517
James Hassard $7,918,296
Javier San Martin $7,899,071
Curt Bradshaw $6,373,206
Kenneth A. Myszkowski $6,081,852
Patrick O’Brien $5,123,502
James Hamilton $3,412,877
Tracie Oliver —
Fiscal 2019
Executive Total
Bruce Given, M.D. $3,958,759
Bruce Given $3,958,759
James Hassard —
Javier San Martin —
Curt Bradshaw —
Fiscal 2018
Executive Total
Bruce Given, M.D. $1,552,061
Bruce Given $1,552,061
James Hassard —
Curt Bradshaw —
Javier San Martin —

Executive changes

Person Change Filed
Dr. Matt Cohen, M.D., M.B.A. Appointed 2026-06-16
Daniel Apel Appointed 2025-04-15
Ken Myszkowski
“Mr. Myszkowski’s decision to retire was not the result of any disagreement with the Company.”
Retired 2025-04-15
Douglas Ingram Appointed 2025-02-07
Douglass Given, M.D., Ph.D. Retired 2024-12-18
Hongbo Lu, Ph.D. Appointed 2024-02-22
Marianne De Backer
“Dr. De Backer's decision to resign was based on her recent appointment as Chief Executive Officer and director of Vir Biotechnology, Inc., and did not result from any disagreement with the Company.”
Resigned 2023-02-14
Patrick O'Brien Appointed 2022-07-20
Victoria Vakiener Appointed 2022-05-05
James Hassard Terminated 2021-08-27

Leadership

Key facts CIK 879407 CUSIP 04280A100 13F (30d) 467 filings 442 filers Visit website Investor relations